‘Gonzalez Diet’ to Be Tested in Pancreatic Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 9
Volume 8
Issue 9

NEW YORK-An innovative clinical trial to be conducted at Columbia University is now recruiting patients with advanced pancreatic cancer. The patients will test the effectiveness of the “Gonzalez regimen,” which combines a strict diet of fresh fruits, vegetable juices, dietary supplements, and pancreatic enzyme extracts with a “detoxification” program. John Chabot, MD, a surgical oncologist at Columbia, is the principal investigator.

NEW YORK—An innovative clinical trial to be conducted at Columbia University is now recruiting patients with advanced pancreatic cancer. The patients will test the effectiveness of the “Gonzalez regimen,” which combines a strict diet of fresh fruits, vegetable juices, dietary supplements, and pancreatic enzyme extracts with a “detoxification” program. John Chabot, MD, a surgical oncologist at Columbia, is the principal investigator.

The researchers are seeking 72 to 90 patients with advanced pancreatic cancer for the phase III randomized study, which is being sponsored by the NCI’s newly established Office of Cancer Complementary and Alternative Medicine. Half the patients will receive standard therapy with gemcitabine (Gemzar), while the other half will take the Gonzalez regimen.

Pilot Study Promising

The trial, which was given a 5-year, $250,000 grant, is applying scientific methods to assess the efficacy of this alternative treatment. The NCI agreed to test the regimen after Nicholas Gonzalez, MD, a New York endocrinologist, conducted a pilot study of his protocol from 1993 to 1996. The results, reported earlier this year in Nutrition and Cancer, showed that 9 of 11 pancreatic patients survived for 1 year, five survived for 2 years, and four survived for 3 years.

For information about patient entry to the trial, contact Michelle Gabay, RN (212-305-9468) at Columbia Presbyterian Cancer Center.

Recent Videos
Only a few groups of patients get screened for pancreatic cancer, those with a genetic risk or pancreatic cysts among them, which can increase lethality for unidentified populations.
The development of RAS-directed vaccines may help decrease the likelihood of disease recurrence in patients undergoing treatment for pancreatic cancer.
Related Content